# TYRA catalysts: Tyra Biosciences, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/tyra/catalysts

> Tyra Biosciences, Inc. (TYRA) has 6 upcoming catalysts. The next is the tyra-300 60mg primary completion, February 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Tyra Biosciences, Inc. |
| Ticker | TYRA (Nasdaq) |
| SEC CIK | 1863127 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/tyra |

## Cash runway

Cash $456.0M as of 2026-09-30; quarterly burn $32.2M; about 42.5 months of runway at that rate (XBRL company facts, accession 0001193125-26-454481).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Oct 2024 | [Dabogratinib interim data readout](https://sec-api.dev/pdufa/dabogratinib) | TYRA |  | completed, positive | "In October 2024, we reported interim data showing a 50% response rate (5/10) in FGFR3 positive patients who received 90 mg daily of oral dabogratinib, with a 100% disease control rate, and favorable safety results demonstrating infrequent FGFR2 and 1 associated toxicities." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1863127/000119312526085490/tyra-20251231.htm)) |
| March 27, 2025 | [Tyra Biosciences, Inc. earnings report](https://sec-api.dev/companies/tyra/catalysts) | TYRA |  | completed | "Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1863127/000095017025046064/tyra-ex99_1.htm)) |
| May 8, 2025 | [Tyra Biosciences, Inc. earnings report](https://sec-api.dev/companies/tyra/catalysts) | TYRA |  | completed | "Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1863127/000095017025066924/tyra-ex99_1.htm)) |
| June 30, 2025 | [Cancer trial start](https://sec-api.dev/pdufa/cancer) | TYRA |  | completed | "On June 30, 2025, Tyra Biosciences, Inc. (Tyra or the Company) announced the first patient has been dosed in the SURF302 Phase 2 clinical study of TYRA-300 in low-grade, intermediate risk non-muscle invasive bladder cancer (IR NMIBC)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1863127/000119312525152016/d11524d8k.htm)) |
| August 14, 2025 | [Tyra Biosciences, Inc. earnings report](https://sec-api.dev/companies/tyra/catalysts) | TYRA |  | completed | "Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1863127/000095017025108876/tyra-ex99_1.htm)) |
| November 5, 2025 | [Tyra Biosciences, Inc. earnings report](https://sec-api.dev/companies/tyra/catalysts) | TYRA |  | completed | "Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1863127/000119312525266916/tyra-ex99_1.htm)) |
| March 2, 2026 | [Tyra Biosciences, Inc. earnings report](https://sec-api.dev/companies/tyra/catalysts) | TYRA |  | completed | "Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1863127/000119312526085399/tyra-ex99_1.htm)) |
| May 13, 2026 | [Tyra Biosciences, Inc. earnings report](https://sec-api.dev/companies/tyra/catalysts) | TYRA |  | completed | "Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1863127/000119312526220638/tyra-ex99_1.htm)) |
| 2H 2026 | [Dabogratinib interim data readout](https://sec-api.dev/pdufa/dabogratinib) | TYRA |  | scheduled | "The Company remains on track and is expected to report interim results from the safety sentinel cohort - which will include 6-month average height velocity data and safety results - in 2H 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1863127/000119312526085399/tyra-ex99_1.htm)) |
| Aug 2026 | [Cancer interim data readout](https://sec-api.dev/pdufa/cancer) | TYRA |  | scheduled | "- Initial Ph2 data readout from SURF302 expected in August 2026 (n>20 enrolled to date) -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1863127/000119312526220638/tyra-ex99_1.htm)) |
| August 4, 2026 | [Tyra Biosciences, Inc. earnings report](https://sec-api.dev/companies/tyra/catalysts) | TYRA |  | completed | "Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1863127/000119312526332752/tyra-ex99_1.htm)) |
| Q4 2026 | [Achondroplasia interim data readout](https://sec-api.dev/pdufa/achondroplasia) | TYRA |  | scheduled | "- Initial Ph2 data readout from safety sentinel cohort in BEACH301 expected in Q4 2026 (4th dose level cleared) -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1863127/000119312526220638/tyra-ex99_1.htm)) |
| November 10, 2026 | [Tyra Biosciences, Inc. earnings report](https://sec-api.dev/companies/tyra/catalysts) | TYRA |  | completed | "Tyra Biosciences Reports Third Quarter 2026 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1863127/000119312526454474/tyra-ex99_1.htm)) |
| February 2028 | [Tyra-300 60mg primary completion](https://sec-api.dev/pdufa/tyra-300) | TYRA | Low-grade NMIBC; FGFR Gene Amplification; FGFR Gene Alterations | scheduled | "NCT06995677 (Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor Tyra Biosciences, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06995677)) |
| Feb to May 2028 | [Tyra-300 60mg topline data readout](https://sec-api.dev/pdufa/tyra-300) | TYRA | Low-grade NMIBC; FGFR Gene Amplification; FGFR Gene Alterations | scheduled | "NCT06995677 (Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor Tyra Biosciences, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06995677)) |
| January 2030 | [Tyra-300 60mg primary completion](https://sec-api.dev/pdufa/tyra-300) | TYRA | Achondroplasia | scheduled | "NCT06842355 (A Study of TYRA-300 in Children With Achondroplasia: BEACH301): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-01 (ESTIMATED); Lead Sponsor Tyra Biosciences, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06842355)) |
| Jan to Apr 2030 | [Tyra-300 60mg topline data readout](https://sec-api.dev/pdufa/tyra-300) | TYRA | Achondroplasia | scheduled | "NCT06842355 (A Study of TYRA-300 in Children With Achondroplasia: BEACH301): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-01 (ESTIMATED); Lead Sponsor Tyra Biosciences, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06842355)) |
| October 2030 | [Dabogratinib (tyra-300) 60mg primary completion](https://sec-api.dev/pdufa/dabogratinib-tyra-300) | TYRA | Low Grade Upper Tract Urothelial Carcinoma | scheduled | "NCT07265947 (Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-10 (ESTIMATED); Lead Sponsor Tyra Biosciences, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07265947)) |
| Oct 2030 to Jan 2031 | [Dabogratinib (tyra-300) 60mg topline data readout](https://sec-api.dev/pdufa/dabogratinib-tyra-300) | TYRA | Low Grade Upper Tract Urothelial Carcinoma | scheduled | "NCT07265947 (Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-10 (ESTIMATED); Lead Sponsor Tyra Biosciences, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07265947)) |

## Drugs

- [Achondroplasia](https://sec-api.dev/pdufa/achondroplasia): 
- [Dabogratinib](https://sec-api.dev/pdufa/dabogratinib): 
- [Dabogratinib (tyra-300) 60mg](https://sec-api.dev/pdufa/dabogratinib-tyra-300): Low Grade Upper Tract Urothelial Carcinoma
- [Tyra-300 60mg](https://sec-api.dev/pdufa/tyra-300): Low-grade NMIBC, Achondroplasia

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/tyra/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "TYRA catalysts: Tyra Biosciences, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/tyra/catalysts

```bibtex
@misc{secapidev_companies_tyra_catalysts_20261116,
  title        = {TYRA catalysts: Tyra Biosciences, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/tyra/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_tyra_catalysts_20261116","title":"TYRA catalysts: Tyra Biosciences, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/tyra/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
